These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26945262)

  • 21. Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.
    Ortel TL
    Hematology Am Soc Hematol Educ Program; 2009; ():225-32. PubMed ID: 20008202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.
    Saccullo G; Malato A; Raso S; Santoro M; Zammit V; Casuccio A; Siragusa S
    Am J Hematol; 2012 Apr; 87(4):388-91. PubMed ID: 22374861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of anticoagulant treatment in cancer patients.
    Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
    Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical studies with anticoagulants to improve survival in cancer patients.
    Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I
    Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current status of anticoagulants].
    Oger E; Mottier D
    Presse Med; 2000 May 27-Jun 3; 29(19):1079-82. PubMed ID: 10874921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy.
    Al-Samkari H; Connors JM
    Blood Adv; 2019 Nov; 3(22):3770-3779. PubMed ID: 31770442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of deep vein thrombosis in cancer patients.
    Lee AY
    Semin Thromb Hemost; 2007 Oct; 33(7):699-706. PubMed ID: 18000798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticoagulant therapy: basic principles, classic approaches and recent developments.
    Sinauridze EI; Panteleev MA; Ataullakhanov FI
    Blood Coagul Fibrinolysis; 2012 Sep; 23(6):482-93. PubMed ID: 22732252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.
    Monreal M; Zacharski L; Jiménez JA; Roncales J; Vilaseca B
    J Thromb Haemost; 2004 Aug; 2(8):1311-5. PubMed ID: 15304036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia.
    Pendleton RC; Rodgers GM; Hull RD
    Clin Chest Med; 2010 Dec; 31(4):691-706. PubMed ID: 21047576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
    ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
    Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management.
    Levi MM; Eerenberg E; Löwenberg E; Kamphuisen PW
    Neth J Med; 2010 Feb; 68(2):68-76. PubMed ID: 20167958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia.
    Vinholt PJ; Alnor A; Nybo M; Hvas AM
    Platelets; 2016 Sep; 27(6):547-54. PubMed ID: 27025360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective evaluation of the clinical use of prothrombin complex concentrate for the reversal of anticoagulation with vitamin K antagonists.
    Cruz JL; Moss MC; Chen SL; Hansen KM; Amerine LB
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):378-82. PubMed ID: 25688457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
    Warkentin TE
    Thromb Haemost; 2008 Jan; 99(1):2-3. PubMed ID: 18217128
    [No Abstract]   [Full Text] [Related]  

  • 37. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
    Ortel TL; Gockerman JP; Califf RM; McCann RL; O'Connor CM; Metzler DM; Greenberg CS
    Thromb Haemost; 1992 Mar; 67(3):292-6. PubMed ID: 1379384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A benchmark for platelet count monitoring with low-molecular-weight heparin: expanding implementation of National Patient Safety Goals.
    Spinler SA
    Ann Pharmacother; 2009 Sep; 43(9):1519-21. PubMed ID: 19690223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia.
    Joseph L; Casanegra AI; Dhariwal M; Smith MA; Raju MG; Militello MA; Gomes MP; Gornik HL; Bartholomew JR
    J Thromb Haemost; 2014 Jul; 12(7):1044-53. PubMed ID: 24766902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia.
    Leader A; Gurevich-Shapiro A; Spectre G
    Thromb Res; 2020 Jul; 191 Suppl 1():S68-S73. PubMed ID: 32736782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.